Equity Tips

header ads

Market ends with marginal gains, Nifty below 10,800; Bharti Airtel, Sun Pharma top gainers



Benchmark indices erased all its morning gains in the final hour of trading as some selling pressure was seen in metal, energy, realty stocks which pulled the Nifty below 10,800.

The Sensex was up 39.80 points at 35,483 and the Nifty up 19.30 points at 10,787. The market breadth was positive with about 1517 shares have advanced, 1162 shares declined, and 151 shares are unchanged.

Bharti Airtel, Sun Pharma, IndusInd Bank, Maruti Suzuki and Dr Reddys Labs are the top gainers on the Sensex.


HEADLINES OF THE DAY

Tata Power’s 100% subsidiary Tata Power Renewable Energy (TPREL) has won a 150 MW Solar PV project on the long term basis in Maharashtra.

The construction arm of L&T has won orders worth Rs 2210 crore across two business segments.

Natco Pharma rose 3.6 percent as company has launched a generic version of Posaconazole Injection, 300 mg/16.7ml, under its brand POSANAT.

Alembic Pharmaceuticals rose 9 percent as company received United States Food & Drug Administration (USFDA) approval for Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg.

Shares of Welspun Corp added 3.6 percent as company bagged an order for supply of API pipes.

Shares of Sun Pharma continued its gains from Friday, rising over a percent on Monday.


NIFTY RESISTANCE AND SUPPORT

The NIFTY will now have Resistance 10875 after that next resistance will be 10950. The support for nifty will be 10680 and next support for nifty will be 10620.
BANK NIFTY RESISTANCE AND SUPPORT

The BANK NIFTY will now have Resistance 26800 after that next resistance will be 27050. The support for nifty will be 26285 and next support for nifty will be 26135.

For more update you can contact us :

CapitalStars Financial Research          Forex trading tips        stock market tips           Share Tips Expert 

Get free trial Click here: http://www.capitalstars.com/free-trial

www.capitalstars.com |T:+91-9977499927 , 0731-6690000






Post a Comment

0 Comments